# Upadacitinib for Immune Checkpoint Inhibitor–Related Dermatitis: A Nonrandomized Clinical Trial

## TL;DR

This study explores using upadacitinib to treat severe skin reactions caused by cancer immunotherapy drugs.

## Contribution

The study evaluates upadacitinib as a potential treatment for immune checkpoint inhibitor–related dermatitis in a clinical trial setting.

## Key findings

- Oral upadacitinib was assessed for safety and efficacy in treating severe immune checkpoint inhibitor–related dermatitis.
- The trial provides insights into managing dermatitis caused by cancer immunotherapy.

## Abstract

This nonrandomized clinical trial examines the safety and efficacy of oral upadacitinib in the treatment of patients with severe immune checkpoint inhibitor–related dermatitis.